Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Feb;25(2):228-231.
doi: 10.1111/1756-185X.14258. Epub 2021 Dec 9.

Janus kinase inhibition in induction treatment of anti-MDA5 juvenile dermatomyositis-associated rapidly progressive interstitial lung disease

Poh Lin Pauline Chan Ng  1   2 , Archana Mopur  1 , Daniel Yam Thiam Goh  1   2 , Mahesh Babu Ramamurthy  1   2 , Michael Teik Chung Lim  1   2 , Lee Kean Lim  1 , Pei Ling Ooi  1 , Elizabeth Youning Ang  1   2
Affiliations
Case Reports

Janus kinase inhibition in induction treatment of anti-MDA5 juvenile dermatomyositis-associated rapidly progressive interstitial lung disease

Poh Lin Pauline Chan Ng et al. Int J Rheum Dis. 2022 Feb.

Abstract

Tofacitinib has an important role in pediatric rapidly progressive interstitial lung disease (ILD) associated with juvenile dermatomyositis (JDM), an otherwise potentially fatal condition. It may be useful in induction of remission and can be used safely to maintain remission. Serum ferritin and interleukin-18 are useful markers for tracking activity and response of JDM-associated ILD.

Keywords: clinical aspects

PubMed Disclaimer

References

REFERENCES

    1. Aeschlimann FA, Frémond ML, Duffy D, et al. A child with severe juvenile dermatomyositis treated with ruxolitinib [published correction appears in brain. 2019 Jan 1;142(1):e3]. Brain. 2018;141(11):e80.
    1. Papadopoulou C, Hong Y, Omoyinmi E, Brogan PA, Eleftheriou D. Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. Brain. 2019;142(3):e8.
    1. Kim H, Dill S, O'Brien M, et al. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Ann Rheum Dis. 2021;80(3):406-408.
    1. Sabbagh S, Almeida de Jesus A, Hwang S, et al. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain. 2019;142(11):e59.
    1. Yu Z, Wang L, Quan M, Zhang T, Song H. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review. Rheumatology (Oxford). 2021;60(4):1700-1707.

Publication types

MeSH terms

LinkOut - more resources